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In hippocampal pyramidal neurons, calcium entry following an action potential burst results in a slow
afterhyperpolarization (sAHP) that critically regulates subsequent excitability. Although this potas-
sium current was described two decades ago, the mechanism whereby the rise in intracellular
calcium generates the sAHP was, until now, not known. In this issue of Neuron, Tzingounis et al.
now show that calcium binding to hippocalcin, a member of the NCS family, is one of the necessary
steps involved in production of the sAHP.
Open access under CC BY license.In hippocampal and cortical pyramidal
neurons, the calcium entry that ac-
companies a burst of action potentials
triggers a long-lasting hyperpolariza-
tion called the slow afterhyperpolari-
zation (sAHP) that lasts for several sec-
onds. This is important physiologically
because it inhibits subsequent action
potentials and limits the frequency of
repetitive action potential discharges
(‘‘spike frequency adaptation’’). Fur-
thermore, the sAHP is powerfully in-
hibited by several neurotransmitters,
such as noradrenaline, acetylcholine,
and serotonin, resulting in a strikingly
enhanced neuronal excitability. This
is thought to underlie some forms
of learning and memory (Disterhoft
et al., 2004). However, in spite of the
fact that the sAHP, and the underlying
potassium current (IsAHP), were first
described two decades ago (Alger
andNicoll,1980;LancasterandAdams,
1986), the mechanism whereby cal-
cium activates the current has re-
mained a puzzle. The search for the
solution is not helped by the fact that
the molecular nature of the sAHP chan-
nels is not known (Stocker et al., 2004).
One of the most challenging fea-
tures of IsAHP is that, although the rise
in intracellular calcium following an ac-
tion potential is virtually instantaneous,
the current itself requires several hun-
dred milliseconds to reach its peak.
Several suggestions as to why this
should be so have been made, such
as intermediation of a ‘‘second mes-
senger’’ (Schwindt et al., 1988), buff-
ered diffusion from the source of
calcium to the responsive potassium
channels (LancasterandZucker,1994),delayed facilitation of the calcium cur-
rent following an action potential burst
(Marrion and Tavalin, 1998), and slow
kinetic responses of the potassium
channels to calcium (Sah and Clem-
ents, 1999).
The Nicoll lab, with their collabora-
tors, have now returned to this ques-
tion (Tzingounis et al., 2007), and
have come up with a very interesting
solution—namely, that there is a sec-
ond messenger, in the form of the dif-
fusible calcium binding protein hip-
pocalcin. Their principal evidence for
this is that IsAHP was very substantially
reduced in hippocampal neurons
from mice in which the hippocalcin
gene was disrupted. Though the au-
thors do not measure Ca2+ transients
directly, they do show that (in contrast
to IsAHP), the current carried by another
set of calcium-activated potassium
channels, the SK2 (KCa2.2) channels
(Stocker et al., 2004), was not reduced
but actually enhanced in these knock-
outs. SK channels are activated di-
rectly by calcium through attached cal-
modulin molecules (Xia et al., 1998),
and hence, unlike the sAHP channels,
track the Ca2+ transient with reason-
able fidelity. Thus, for SK channels,
hippocalcin acts simply as an endoge-
nous diffusible buffer, reducing sub-
membrane Ca2+ by transporting it into
the bulk cytoplasm—rather like BAPTA
or EGTA, as the authors show.
So what is hippocalcin and how
does it work? Hippocalcin is a member
of the neuronal calcium sensor (NCS)
family of calcium binding proteins
(Burgoyne et al., 2004), with four po-
tential Ca2+ binding EF hands (thoughNeuron 53, Feonly two may be functionally occu-
pied). The archetype of this family is
the photoreceptor protein recoverin
(also known as S-modulin or visinin),
which mediates calcium-dependent
inhibition of rhodopsin kinase and
hence assists in the adaptation of the
phototransduction pathway. This pro-
tein is myristoylated at the N-terminal,
but the myristoyl group is normally
buried within a hyrdophobic pocket
(Figure 1, left side). However, when it
binds Ca2+ (at EF hands 2 and 3), the
myristoyl group ‘‘flips out’’—a process
termed a ‘‘myristoyl switch’’ (Ames
et al., 1997); this promotes transloca-
tion to the cell membrane where the
myristoyl moiety becomes embedded
in the membrane lipid layer (Figure 1,
right side).
Hippocalcin behaves similarly and
rapidly translocates to membrane sites
following a rise in intracellular Ca2+
(O’Callaghan et al., 2003). Indeed,
such a translocation has been ob-
served in hippocampal neurons during
electrical activity (P. Belan et al., 2005,
Soc. Neurosci., abstract), as Tzingou-
nis et al. note. Furthermore, hippocal-
cin is strongly expressed in the hippo-
campus and cortex, and responds to
Ca2+ within a range (200–800 nM;
O’Callaghan et al., 2003) that matches
the sensitivity of the AHP current.
Thus, the scenario would be that cal-
cium enters the cytoplasm where it
binds to hippocalcin, then induces a
myristoyl switch whereupon calcium-
bound hippocalcin translocates to (and
inserts in) the membrane to generate
the sAHP. In support of this myristoyla-
tion requirement, Tzingounis et al. gobruary 15, 2007 ª2007 Elsevier Inc. 467
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Previewson to show that transfection of hippo-
calcin into cultured neurons generates
an IsAHP, whereas a mutated form that
could not be myristoylated did not.
Of course, as with any such novel
hypothesis, there are some outstand-
ing questions. For example, IsAHP was
not completely lost in the hippocalcin
knockouts, even though (presumably)
there was no hippocalcin (Kobayashi
et al., 2005). Also, the residual current
appeared strikingly insensitive to nor-
adrenaline compared with that from
wild-type mice. Assuming that the re-
sidual current is carried by the same
channels, does this mean that there is
a ‘‘reserve’’ second messenger (per-
haps operating at higher levels of
Ca2+, as Figure 3 in Tzingounis et al.
might suggest)? And, if so, does this
Figure 1. Structure of Myristoylated
Recoverin
In the resting state (left side) the N-terminal
myristoyl group (arrow) is marked. Two Ca2+
ions (right side, green balls) bind to the EF-2
and EF-3 hands and induce a conformational
change exposing the myristoyl group, which
then inserts into the membrane. Reprinted
from Burgoyne et al. (2004), with permission
from Elsevier.468 Neuron 53, February 15, 2007 ª2007messenger act differently from hippo-
calcin, such as to occlude the effect
(PKA-mediated phosphorylation) of
noradrenaline? Or perhaps endoge-
nous hippocalcin actually enhances
the sensitivity to noradrenaline by in-
hibiting phosphodiesterase. [Haynes
et al. (2006) have reported that hippo-
calcin binds to phosphodiesterase.]
In this context, it would have been
useful to know whether the residual
current was equally insensitive to a
transmitter acting through a different
pathway, such as acetylcholine.
Finally, when hippocalcin gets to the
membrane, how does it activate the
sAHP channels? Does it interact di-
rectly with the channel? Or is a third
messenger system involved? Hippo-
calcin binds strongly to phosphati-
dylinositol-4,5-bisphosphate (PIP2)
(O’Callaghan et al., 2005), so one pos-
sibility is that the channels are held shut
by membrane PIP2 and then open
when hippocalcin sequesters chan-
nel-associated PIP2 molecules. The fi-
nal resolution of these questions may
have to wait until the molecular identity
of the true sAHP channel is revealed.
The availability of new and selective
sAHP blockers (Shah et al., 2006) may
help here. This new information about
hippocalcin will be particularly crucial
since we will no longer have to look
for calcium-activated channels, but in-
stead for channels that can be acti-
vated by hippocalcin.
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